Induction of Cellular Immune Responses to Tumor Cells and Peptides in Colorectal Cancer Patients by Vaccination with SART3 Peptides
The tumor-rejection antigen SART3 possesses two antigenic epitopes (SART3 109–118 and SART3 315–323 ) capable of inducing HLA-A24-restricted and tumor-specific CTLs. To determine its safety and ability to generate antitumor immune responses, 12 patients with advanced colorectal cancer were administe...
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research 2001-12, Vol.7 (12), p.3950-3962 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3962 |
|---|---|
| container_issue | 12 |
| container_start_page | 3950 |
| container_title | Clinical cancer research |
| container_volume | 7 |
| creator | MIYAGI, Yoshiaki IMAI, Nobue SHIROUZU, Kazuo YAMANA, Hideaki ITOH, Kyogo SASATOMI, Teruo YAMADA, Akira MINE, Takashi KATAGIRI, Kazuko NAKAGAWA, Masami MUTO, Akira OKOUCHI, Shinya ISOMOTO, Hiroharu |
| description | The tumor-rejection antigen SART3 possesses two antigenic epitopes (SART3 109–118 and SART3 315–323 ) capable of inducing HLA-A24-restricted and tumor-specific CTLs. To determine its safety and ability to generate antitumor
immune responses, 12 patients with advanced colorectal cancer were administered s.c. vaccinations of these peptides. No severe
adverse events were associated with the vaccinations. Significant levels of increased cellular immune responses to both HLA-A24 + colon cancer cells and the vaccinated peptide were observed in the postvaccination peripheral blood mononuclear cells in
7 of 11 and 7 of 10 patients tested, respectively, and the higher responses were observed in those patients vaccinated with
the highest dose (3 mg/injection) of the peptides. These results encourage further development of SART3 peptide vaccine for
colorectal cancer patients. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_72367508</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72367508</sourcerecordid><originalsourceid>FETCH-LOGICAL-h270t-765a5a011a2424c1b541183fb03708c3cec27cf3803339171d363f8ea38bf4a63</originalsourceid><addsrcrecordid>eNpF0EFrFTEQB_BFFFurX0FyUbwsJJlkkx7LovVBwdI-vS6z2Vk3sps8kyylZ7-4y-vTnmZgfsww_xfVudDa1CAb_XLrubE1VyDPqjc5_-JcKMHV6-pMCKOFsua8-rMLw-qKj4HFkbU0z-uMie2WZQ3E7igfYsiUWYlsvy4xHUlmGAZ2S4fih23mA2vjHBO5gjNrMThK7BaLp1Ay6x_ZD3TOBzxeefBlYvdXd3v4v-Bt9WrEOdO7U72ovn_5vG-_1jffrnft1U09ScNLbRqNGrkQKJVUTvRaCWFh7DkYbh04ctK4ESwHgEthxAANjJYQbD8qbOCi-vi095Di75Vy6Raf3fYPBopr7oyExmhuN_j-BNd-oaE7JL9geuz-xbaBDyeA2eE8pu1nn58dKKHBys19enKT_zk9-ESdO6aTKBMmN3WmE7KDS83hLzGmhPE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72367508</pqid></control><display><type>article</type><title>Induction of Cellular Immune Responses to Tumor Cells and Peptides in Colorectal Cancer Patients by Vaccination with SART3 Peptides</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>MIYAGI, Yoshiaki ; IMAI, Nobue ; SHIROUZU, Kazuo ; YAMANA, Hideaki ; ITOH, Kyogo ; SASATOMI, Teruo ; YAMADA, Akira ; MINE, Takashi ; KATAGIRI, Kazuko ; NAKAGAWA, Masami ; MUTO, Akira ; OKOUCHI, Shinya ; ISOMOTO, Hiroharu</creator><creatorcontrib>MIYAGI, Yoshiaki ; IMAI, Nobue ; SHIROUZU, Kazuo ; YAMANA, Hideaki ; ITOH, Kyogo ; SASATOMI, Teruo ; YAMADA, Akira ; MINE, Takashi ; KATAGIRI, Kazuko ; NAKAGAWA, Masami ; MUTO, Akira ; OKOUCHI, Shinya ; ISOMOTO, Hiroharu</creatorcontrib><description>The tumor-rejection antigen SART3 possesses two antigenic epitopes (SART3 109–118 and SART3 315–323 ) capable of inducing HLA-A24-restricted and tumor-specific CTLs. To determine its safety and ability to generate antitumor
immune responses, 12 patients with advanced colorectal cancer were administered s.c. vaccinations of these peptides. No severe
adverse events were associated with the vaccinations. Significant levels of increased cellular immune responses to both HLA-A24 + colon cancer cells and the vaccinated peptide were observed in the postvaccination peripheral blood mononuclear cells in
7 of 11 and 7 of 10 patients tested, respectively, and the higher responses were observed in those patients vaccinated with
the highest dose (3 mg/injection) of the peptides. These results encourage further development of SART3 peptide vaccine for
colorectal cancer patients.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>PMID: 11751487</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Adult ; Aged ; Antigens, Neoplasm - adverse effects ; Antigens, Neoplasm - immunology ; Antigens, Neoplasm - therapeutic use ; Antineoplastic agents ; Biological and medical sciences ; Cancer Vaccines - adverse effects ; Cancer Vaccines - immunology ; Cancer Vaccines - therapeutic use ; Colorectal Neoplasms - immunology ; Colorectal Neoplasms - mortality ; Colorectal Neoplasms - pathology ; Colorectal Neoplasms - therapy ; Epitopes - immunology ; Female ; HLA-A Antigens - immunology ; HLA-A24 Antigen ; Humans ; Hypersensitivity, Immediate ; Immunity, Cellular ; Immunoglobulin E - blood ; Immunoglobulin G - blood ; Immunotherapy ; Male ; Medical sciences ; Middle Aged ; Neoplasm Staging ; Pharmacology. Drug treatments ; RNA-Binding Proteins - adverse effects ; RNA-Binding Proteins - immunology ; RNA-Binding Proteins - therapeutic use ; Survival Rate ; Time Factors</subject><ispartof>Clinical cancer research, 2001-12, Vol.7 (12), p.3950-3962</ispartof><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13415382$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11751487$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MIYAGI, Yoshiaki</creatorcontrib><creatorcontrib>IMAI, Nobue</creatorcontrib><creatorcontrib>SHIROUZU, Kazuo</creatorcontrib><creatorcontrib>YAMANA, Hideaki</creatorcontrib><creatorcontrib>ITOH, Kyogo</creatorcontrib><creatorcontrib>SASATOMI, Teruo</creatorcontrib><creatorcontrib>YAMADA, Akira</creatorcontrib><creatorcontrib>MINE, Takashi</creatorcontrib><creatorcontrib>KATAGIRI, Kazuko</creatorcontrib><creatorcontrib>NAKAGAWA, Masami</creatorcontrib><creatorcontrib>MUTO, Akira</creatorcontrib><creatorcontrib>OKOUCHI, Shinya</creatorcontrib><creatorcontrib>ISOMOTO, Hiroharu</creatorcontrib><title>Induction of Cellular Immune Responses to Tumor Cells and Peptides in Colorectal Cancer Patients by Vaccination with SART3 Peptides</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>The tumor-rejection antigen SART3 possesses two antigenic epitopes (SART3 109–118 and SART3 315–323 ) capable of inducing HLA-A24-restricted and tumor-specific CTLs. To determine its safety and ability to generate antitumor
immune responses, 12 patients with advanced colorectal cancer were administered s.c. vaccinations of these peptides. No severe
adverse events were associated with the vaccinations. Significant levels of increased cellular immune responses to both HLA-A24 + colon cancer cells and the vaccinated peptide were observed in the postvaccination peripheral blood mononuclear cells in
7 of 11 and 7 of 10 patients tested, respectively, and the higher responses were observed in those patients vaccinated with
the highest dose (3 mg/injection) of the peptides. These results encourage further development of SART3 peptide vaccine for
colorectal cancer patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Antigens, Neoplasm - adverse effects</subject><subject>Antigens, Neoplasm - immunology</subject><subject>Antigens, Neoplasm - therapeutic use</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Cancer Vaccines - adverse effects</subject><subject>Cancer Vaccines - immunology</subject><subject>Cancer Vaccines - therapeutic use</subject><subject>Colorectal Neoplasms - immunology</subject><subject>Colorectal Neoplasms - mortality</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Colorectal Neoplasms - therapy</subject><subject>Epitopes - immunology</subject><subject>Female</subject><subject>HLA-A Antigens - immunology</subject><subject>HLA-A24 Antigen</subject><subject>Humans</subject><subject>Hypersensitivity, Immediate</subject><subject>Immunity, Cellular</subject><subject>Immunoglobulin E - blood</subject><subject>Immunoglobulin G - blood</subject><subject>Immunotherapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Pharmacology. Drug treatments</subject><subject>RNA-Binding Proteins - adverse effects</subject><subject>RNA-Binding Proteins - immunology</subject><subject>RNA-Binding Proteins - therapeutic use</subject><subject>Survival Rate</subject><subject>Time Factors</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0EFrFTEQB_BFFFurX0FyUbwsJJlkkx7LovVBwdI-vS6z2Vk3sps8kyylZ7-4y-vTnmZgfsww_xfVudDa1CAb_XLrubE1VyDPqjc5_-JcKMHV6-pMCKOFsua8-rMLw-qKj4HFkbU0z-uMie2WZQ3E7igfYsiUWYlsvy4xHUlmGAZ2S4fih23mA2vjHBO5gjNrMThK7BaLp1Ay6x_ZD3TOBzxeefBlYvdXd3v4v-Bt9WrEOdO7U72ovn_5vG-_1jffrnft1U09ScNLbRqNGrkQKJVUTvRaCWFh7DkYbh04ctK4ESwHgEthxAANjJYQbD8qbOCi-vi095Di75Vy6Raf3fYPBopr7oyExmhuN_j-BNd-oaE7JL9geuz-xbaBDyeA2eE8pu1nn58dKKHBys19enKT_zk9-ESdO6aTKBMmN3WmE7KDS83hLzGmhPE</recordid><startdate>20011201</startdate><enddate>20011201</enddate><creator>MIYAGI, Yoshiaki</creator><creator>IMAI, Nobue</creator><creator>SHIROUZU, Kazuo</creator><creator>YAMANA, Hideaki</creator><creator>ITOH, Kyogo</creator><creator>SASATOMI, Teruo</creator><creator>YAMADA, Akira</creator><creator>MINE, Takashi</creator><creator>KATAGIRI, Kazuko</creator><creator>NAKAGAWA, Masami</creator><creator>MUTO, Akira</creator><creator>OKOUCHI, Shinya</creator><creator>ISOMOTO, Hiroharu</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20011201</creationdate><title>Induction of Cellular Immune Responses to Tumor Cells and Peptides in Colorectal Cancer Patients by Vaccination with SART3 Peptides</title><author>MIYAGI, Yoshiaki ; IMAI, Nobue ; SHIROUZU, Kazuo ; YAMANA, Hideaki ; ITOH, Kyogo ; SASATOMI, Teruo ; YAMADA, Akira ; MINE, Takashi ; KATAGIRI, Kazuko ; NAKAGAWA, Masami ; MUTO, Akira ; OKOUCHI, Shinya ; ISOMOTO, Hiroharu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h270t-765a5a011a2424c1b541183fb03708c3cec27cf3803339171d363f8ea38bf4a63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antigens, Neoplasm - adverse effects</topic><topic>Antigens, Neoplasm - immunology</topic><topic>Antigens, Neoplasm - therapeutic use</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Cancer Vaccines - adverse effects</topic><topic>Cancer Vaccines - immunology</topic><topic>Cancer Vaccines - therapeutic use</topic><topic>Colorectal Neoplasms - immunology</topic><topic>Colorectal Neoplasms - mortality</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Colorectal Neoplasms - therapy</topic><topic>Epitopes - immunology</topic><topic>Female</topic><topic>HLA-A Antigens - immunology</topic><topic>HLA-A24 Antigen</topic><topic>Humans</topic><topic>Hypersensitivity, Immediate</topic><topic>Immunity, Cellular</topic><topic>Immunoglobulin E - blood</topic><topic>Immunoglobulin G - blood</topic><topic>Immunotherapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Pharmacology. Drug treatments</topic><topic>RNA-Binding Proteins - adverse effects</topic><topic>RNA-Binding Proteins - immunology</topic><topic>RNA-Binding Proteins - therapeutic use</topic><topic>Survival Rate</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MIYAGI, Yoshiaki</creatorcontrib><creatorcontrib>IMAI, Nobue</creatorcontrib><creatorcontrib>SHIROUZU, Kazuo</creatorcontrib><creatorcontrib>YAMANA, Hideaki</creatorcontrib><creatorcontrib>ITOH, Kyogo</creatorcontrib><creatorcontrib>SASATOMI, Teruo</creatorcontrib><creatorcontrib>YAMADA, Akira</creatorcontrib><creatorcontrib>MINE, Takashi</creatorcontrib><creatorcontrib>KATAGIRI, Kazuko</creatorcontrib><creatorcontrib>NAKAGAWA, Masami</creatorcontrib><creatorcontrib>MUTO, Akira</creatorcontrib><creatorcontrib>OKOUCHI, Shinya</creatorcontrib><creatorcontrib>ISOMOTO, Hiroharu</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MIYAGI, Yoshiaki</au><au>IMAI, Nobue</au><au>SHIROUZU, Kazuo</au><au>YAMANA, Hideaki</au><au>ITOH, Kyogo</au><au>SASATOMI, Teruo</au><au>YAMADA, Akira</au><au>MINE, Takashi</au><au>KATAGIRI, Kazuko</au><au>NAKAGAWA, Masami</au><au>MUTO, Akira</au><au>OKOUCHI, Shinya</au><au>ISOMOTO, Hiroharu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Induction of Cellular Immune Responses to Tumor Cells and Peptides in Colorectal Cancer Patients by Vaccination with SART3 Peptides</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2001-12-01</date><risdate>2001</risdate><volume>7</volume><issue>12</issue><spage>3950</spage><epage>3962</epage><pages>3950-3962</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>The tumor-rejection antigen SART3 possesses two antigenic epitopes (SART3 109–118 and SART3 315–323 ) capable of inducing HLA-A24-restricted and tumor-specific CTLs. To determine its safety and ability to generate antitumor
immune responses, 12 patients with advanced colorectal cancer were administered s.c. vaccinations of these peptides. No severe
adverse events were associated with the vaccinations. Significant levels of increased cellular immune responses to both HLA-A24 + colon cancer cells and the vaccinated peptide were observed in the postvaccination peripheral blood mononuclear cells in
7 of 11 and 7 of 10 patients tested, respectively, and the higher responses were observed in those patients vaccinated with
the highest dose (3 mg/injection) of the peptides. These results encourage further development of SART3 peptide vaccine for
colorectal cancer patients.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>11751487</pmid><tpages>13</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 2001-12, Vol.7 (12), p.3950-3962 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72367508 |
| source | MEDLINE; American Association for Cancer Research; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult Aged Antigens, Neoplasm - adverse effects Antigens, Neoplasm - immunology Antigens, Neoplasm - therapeutic use Antineoplastic agents Biological and medical sciences Cancer Vaccines - adverse effects Cancer Vaccines - immunology Cancer Vaccines - therapeutic use Colorectal Neoplasms - immunology Colorectal Neoplasms - mortality Colorectal Neoplasms - pathology Colorectal Neoplasms - therapy Epitopes - immunology Female HLA-A Antigens - immunology HLA-A24 Antigen Humans Hypersensitivity, Immediate Immunity, Cellular Immunoglobulin E - blood Immunoglobulin G - blood Immunotherapy Male Medical sciences Middle Aged Neoplasm Staging Pharmacology. Drug treatments RNA-Binding Proteins - adverse effects RNA-Binding Proteins - immunology RNA-Binding Proteins - therapeutic use Survival Rate Time Factors |
| title | Induction of Cellular Immune Responses to Tumor Cells and Peptides in Colorectal Cancer Patients by Vaccination with SART3 Peptides |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T17%3A10%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Induction%20of%20Cellular%20Immune%20Responses%20to%20Tumor%20Cells%20and%20Peptides%20in%20Colorectal%20Cancer%20Patients%20by%20Vaccination%20with%20SART3%20Peptides&rft.jtitle=Clinical%20cancer%20research&rft.au=MIYAGI,%20Yoshiaki&rft.date=2001-12-01&rft.volume=7&rft.issue=12&rft.spage=3950&rft.epage=3962&rft.pages=3950-3962&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E72367508%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72367508&rft_id=info:pmid/11751487&rfr_iscdi=true |